EP0978275A1 — Solid pharmaceutical dosage form with controlled drug release
Assigned to Pharma Pass SA · Expires 2000-02-09 · 26y expired
What this patent protects
The invention relates to a pharmaceutical dosage form comprising a core containing at least part of an active ingredient, and a functional film coating ensuring controlled onset of the release of the active ingredient contained in the core. The film coating comprises at least one…
USPTO Abstract
The invention relates to a pharmaceutical dosage form comprising a core containing at least part of an active ingredient, and a functional film coating ensuring controlled onset of the release of the active ingredient contained in the core. The film coating comprises at least one excipient ensuring gastro-resistance and one substance creating an acidic pH in the functional film coating. The invention allows a lag time between the administration of the pharmaceutical dosage form and the beginning of the release of the drug, said lag time being adjustable to a predefined duration by appropriate formulation. As an example of therapeutic application, the invention provides a dosage form that may release its active ingredient a few hours after administration and is of great interest for reducing some nocturnal occurring diseases, such as ischemic heart attack, asthma or arthritis.
Drugs covered by this patent
- Prilosec (omeprazole) · AstraZeneca (originally Astra AB)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.